Clinical Trial Update: Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Presatovir in hematopoietic cell transplant recipients with lower respiratory tract RSV infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Presatovir (GS-5806)

Snippet

Sponsor: Gilead Sciences | Conditions: Respiratory Syncytial Virus Infection | Phase 2 | Status: COMPLETED | Results posted: 2018-05-11